CSIMarket
 
Aptose Biosciences Inc   (APTO)
Other Ticker:  
 
 
Price: $1.5200 $0.12 8.571%
Day's High: $1.52 Week Perf: -3.8 %
Day's Low: $ 1.37 30 Day Perf: -22.05 %
Volume (M): 71 52 Wk High: $ 6.60
Volume (M$): $ 108 52 Wk Avg: $2.56
Open: $1.40 52 Wk Low: $0.36



 Market Capitalization (Millions $) 10
 Shares Outstanding (Millions) 7
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -49
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) 0

Aptose Biosciences Inc
Aptose Biosciences Inc is a Canadian biotech company that specializes in the research and development of targeted therapies for cancer treatment. The company focuses on developing drugs that target specific molecular pathways involved in cancer growth and survival. Aptose Biosciences utilizes innovative technologies and collaborations with academic institutions and industry partners to discover and develop promising treatments. Their goal is to provide effective therapies that improve patient outcomes and address unmet medical needs in oncology.


   Company Address: 251 Consumers Road, Suite 1105 Toronto 0 ON
   Company Phone Number: 479-9828   Stock Exchange / Ticker: NASDAQ APTO
   APTO is expected to report next financial results on March 22, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Financing Agreement

Aptose Therapeutics and Hanmi Pharmaceutical Join Forces in $12.4 Million Investment to Revolutionize Oncology Treatments

Published Fri, Jan 26 2024 1:00 PM UTC

Aptose Therapeutics Forges Strategic Partnership with Hanmi Pharmaceutical Alongside Successful Public Offering and Private Placement
In a significant move towards fortifying its position in the oncology market, Canadian biotechnology company Aptose Therapeutics recently announced the pricing of an $8.4 million public offering, combined with a concurrent $4 million priva...

Clinical Study

Tuspetinib: A Beacon of Hope for Relapsed/Refractory AML Patients - Promising Phase 1/2 Study Data Presented at the 2023 ASH Annual Meeting

Published Sat, Dec 9 2023 11:30 PM UTC



In a momentous breakthrough in the field of leukemia treatment, Aptose Biosciences' experimental drug Tuspetinib (TUS) has exhibited remarkable effectiveness in an ongoing Phase 1/2 study for patients with relapsed or refractory acute myeloid leukemia (AML). The impressive clinical data from this study was recently presented during the prestigious 2023 ASH Annual M...

Aptose Biosciences Inc

Aptose Biosciences Inc Reports Steady Decrease in Corporate Conduct during Third Quarter of 2023 Earnings Season



The Biotechnology & Pharmaceuticals sector has been closely examining the third quarter performance of Aptose Biosciences Inc in 2023. Unfortunately, the company's financials have raised significant concerns among insiders, as it reported an operating loss of $-11.681 million for the July to September reporting period. What's more troubling is the absence of any revenue, leaving investors speculating when the company will begin generating income. This bearish article aims to delve deeper into Aptose Biosciences' financial woes and shed light on the potential challenges it faces in the market.
Deteriorating Financial Performances:
Comparing the third quarters of 2022 and 2023, Aptose Biosciences witnessed a further decline in operating loss. The company's operating loss grew from $-10.026 million in 2022 to $-11.681 million in 2023. Such a trend showcases a worrying lack of improvement in the company's financials. Additionally, the lack of revenue has widened the company's shortfall from $-9.777 million to $-11.447 million, highlighting Aptose Biosciences' struggle to generate profits.

Aptose Biosciences Inc

Shareholders Hail Aptose Biosciences Inc's Promising Future, But Is It On Shaky Ground?

The recent performance of Aptose Biosciences Inc has left shareholders optimistic about the company's potential for growth. However, a closer look at the financials raises concerns about the sustainability of this upward trajectory.
During the earnings season of April to June 2023, shareholders did not anticipate any modifications at the top-line. This lack of anticipated growth is a red flag, as it suggests that the company may struggle to generate substantial revenue in the near future. Furthermore, the operating shortfall during this period stood at a staggering $-14.452 million. This indicates that the company's expenses are outpacing its revenue, which is a troubling sign for investors.

Aptose Biosciences Inc

Aptose Biosciences Inc Faces Operating Shortfall of $-14.096 Million in Q1 2023, Striving to Boost Revenue with New Business Strategy

The Biotechnology & Pharmaceuticals sector has been closely monitoring the first quarter earnings for 2023, particularly with regards to the APTO corporation. These researchers have identified an operating shortfall of $-14.096 million during the three-month reporting period from January to March 31, 2023. What's concerning is that the APTO corporation has not generated any revenue during this time.
This trend has been ongoing for some time now, as the corporation has struggled to bring in profits. In response to this challenge, the APTO corporation is pursuing various financial plans to try and secure new product lines in the market. Shareholders are less concerned about the operational behavior of the corporation, and instead are looking forward to a new business strategy that could potentially boost revenue.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com